{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"12"}]}],"title":"Improved in global QoL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"18"}]}],"title":"Stable in global QoL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"2"}]}],"title":"Worsened in global QoL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for global QoL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"11"},{"groupId":"OG006","value":"5"}]}],"title":"Improved in physical functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"38"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"},{"groupId":"OG005","value":"23"},{"groupId":"OG006","value":"23"}]}],"title":"Stable in physical functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"4"}]}],"title":"Worsened in physical functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for physical functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"10"}]}],"title":"Improved in role functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"15"}]}],"title":"Stable in role functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"7"}]}],"title":"Worsened in role functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for role functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"10"}]}],"title":"Improved in emotional functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"20"}]}],"title":"Stable in emotional functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"}]}],"title":"Worsened in emotional functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for emotional functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"9"}]}],"title":"Improved in cognitive functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"34"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"11"}]}],"title":"Stable in cognitive functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"12"}]}],"title":"Worsened in cognitive functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for cognitive functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"13"}]}],"title":"Improved in social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"13"}]}],"title":"Stable in social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"6"}]}],"title":"Worsened in social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for social functioning"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"17"}]}],"title":"Improved in fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"9"}]}],"title":"Stable in fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"6"}]}],"title":"Worsened in fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"6"}]}],"title":"Improved in nausea and vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"28"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"24"}]}],"title":"Stable in nausea and vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"}]}],"title":"Worsened in nausea and vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for nausea and vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"14"}]}],"title":"Improved in pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"13"}]}],"title":"Stable in pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"5"}]}],"title":"Worsened in pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"9"}]}],"title":"Improved in dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"17"},{"groupId":"OG006","value":"15"}]}],"title":"Stable in dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"8"}]}],"title":"Worsened in dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"30"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"19"},{"groupId":"OG006","value":"12"}]}],"title":"Improved in insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"18"},{"groupId":"OG006","value":"15"}]}],"title":"Stable in insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"5"}]}],"title":"Worsened in insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for insomnia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"10"}]}],"title":"Improved in appetite loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"36"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"20"},{"groupId":"OG006","value":"20"}]}],"title":"Stable in appetite loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"2"}]}],"title":"Worsened in appetite loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for appetite loss"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"10"}]}],"title":"Improved in constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"33"},{"groupId":"OG004","value":"29"},{"groupId":"OG005","value":"22"},{"groupId":"OG006","value":"12"}]}],"title":"Stable in constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"10"}]}],"title":"Worsened in constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"6"}]}],"title":"Improved in diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"40"},{"groupId":"OG003","value":"39"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"28"},{"groupId":"OG006","value":"21"}]}],"title":"Stable in diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"5"}]}],"title":"Worsened in diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"9"}]}],"title":"Improved in financial difficulties"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"34"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"26"},{"groupId":"OG006","value":"16"}]}],"title":"Stable in financial difficulties"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"11"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"}]}],"title":"Worsened in financial difficulties"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"}]}],"title":"Missing for financial difficulties"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"43"},{"groupId":"OG005","value":"41"},{"groupId":"OG006","value":"32"}],"units":"Participants"}],"description":"European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ)-C30 (version 3.0) consists of 30 questions assessing 5 functional domains (physical, role, emotional, cognitive and social), global quality of life (QoL), disease/treatment related symptoms (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation and diarrhea), and the perceived financial impact of disease. Each scale was transformed to a range of 0 to 100 using standard EORTC algorithm. For global QoL and functional scales, higher score indicate better performance, and improvement was defined as an increase of at least 10 points, worsening was defined as a decrease of at least 10 points. For symptom scales, higher score indicates worse symptoms, and improvement was defined as a decrease of at least 10 points, worsening was defined as an increase of at least 10 points. All scales which had not improved nor worsened were considered stable.","groups":[{"description":"Treatment-naïve participants with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) with or without asymptomatic central nervous system (CNS) metastases were given PF-06463922 100 mg orally QD on Day -7 (only participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG000","title":"EXP-1 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after only crizotinib therapy were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG001","title":"EXP-2 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after crizotinib therapy and 1 or 2 prior regimens of chemotherapy given before or after crizotinib therapy, or participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 1 ALK inhibitor therapy other than crizotinib with or without any number of prior chemotherapy regimens in any disease setting were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG002","title":"EXP-3 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 2 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG003","title":"EXP-4 (Phase 2)"},{"description":"Participants with advanced ALK-positive NSCLC with or without asymptomatic CNS metastases relapsing after 3 prior lines of ALK inhibitor therapies were given PF-06463922 100 mg orally QD on Day -7 (only for participant scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG004","title":"EXP-5 (Phase 2)"},{"description":"Participants with advanced ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were given PF-06463922 100 mg orally QD on Day -7 (only for participants scheduled for pharmacokinetic evaluation) and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG005","title":"EXP-6 (Phase 2)"},{"description":"Participants with advanced ALK positive or ROS1-positive NSCLC who were treatment naïve or had any number of prior cancer therapies with or without asymptomatic CNS metastases were administered a single dose of a probe substrate alone on Day -2. Participants were given PF-06463922 100 mg orally QD starting on Cycle1 Day 1 and along with probe substrate on Day 15 Cycle 1.","id":"OG006","title":"DDI Sub-study"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patient reported outcome (PRO) evaluable analysis set included all enrolled participants who received at least 1 dose of PF-06463922 and completed a baseline and at least 1 post-baseline PRO assessment.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment to end of treatment (maximum of 7.5 years for Phase 2 and up to a maximum of 6 years approx. for DDI sub study)","title":"Number of Participants Who Improved, Worsened or Remained Stable in EORTC QLQ-C30 (Phase 2 and DDI Sub-study)","type":"SECONDARY","unitOfMeasure":"Participants"}